Clinical Trial

Ketamine and Levetiracetam as Second-line Antiseizure Medication for Status Epilepticus in Children

Study acronym: KLaSSEC
Recruiting Phase 2/3
View on ClinicalTrials.gov →
Record status
This record was last updated July 3, 2025 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
About 40% of children with generalized convulsive status epilepticus (GCSE) are not terminated by first-line benzodiazepines (BDZs), and approximately 50% of BDZ-refractory GCSE are not controlled by second-line antiseizure medications. This study investigates the efficacy of ketamine-levetiracetam combination vs. levetiracetam alone for treating children with BDZ-refractory GCSE.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-06-27.
Status change: Not Yet Recruiting → Recruiting 2025-07-02
Trial Details
NCT Number NCT07046611
Lead Sponsor Sohag University
Conditions Generalized Convulsive Status Epilepticus
Enrollment 124 participants
Start Date 2025-07-02
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-07-01 (estimated)
Updated on ClinicalTrials.gov 2025-07-03